

2ª Convocatoria de "Acceso competitivo" a NANBIOSIS de 2024

Acuerdo de Priorización de Solicitudes de Acceso a NANBIOSIS

por del Comité de Coordinación

NANBIOSIS ofrece acceso a sus servicios a todos los usuarios, nacionales e internacionales, que pueden provenir del sector público o privado, bajo las modalidades de "Acceso Abierto Competitivo" o "Acceso por Demanda". Las solicitudes de acceso seleccionadas en el modo abierto y competitivo obtendrán prioridad en el acceso a la instalación frente a las solicitudes consideradas en "acceso por demanda". Existen dos convocatorias anuales de acceso competitivo.

El proceso de evaluación de dichas solicitudes se lleva a cabo en tres fases:

- Fase interna: Revisión administrativa interna y consulta con las unidades sobre la viabilidad técnica de los accesos solicitados
- Fase externa: Evaluación por el Comité de Acceso
- Priorización de solicitudes en régimen de acceso competitivo por el Comité de Coordinación de NANBIOSIS

En el marco de la 1ª Convocatoria de Acceso Abierto y Competitivo a la ICTS NANBIOSIS en 2024, el Comité de Coordinación de NANBIOSIS, siguiendo la evaluación de solicitudes y la propuesta de priorización emitida por del Comité de Acceso, acuerda:

- Conceder acceso priorizado en "modo abierto y competitivo" a las solicitudes cuyo código de entrada se destaca con fondo verde en la tabla que se muestra a continuación.
- Establecer un orden de prioridad de acceso de dichas solicitudes en modo competitivo, a cada una de las unidades de NANBIOSIS. (Ordenadas de mayor a menor prioridad en la siguiente tabla).
- Considerar como "accesos a demanda" los indicados en las solicitudes cuyo código de entrada tiene fondo blanco en la siguiente tabla. Los accesos derivados de las solicitudes a demanda solo se realizarán una vez cubiertos los "accesos competitivos".

Priorización de Solicitudes de Acceso a NANBIOSIS

Unidad	Solicitud	Descripción Acceso
U01	3818	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	3864	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	3866	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	3870	U1-S03: Protein purification (On-site&Remote) OUTSTANDING

U01	3871	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	3872	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	3810	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	3812	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	3814	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	3800	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	3863	U1-S02. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	3865	U1-S02. Bioproduction of proteins (On-site&Remote) OUTSTANDING
U01	3867	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	3868	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	3869	U1-S03: Protein purification (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U02	3894	U2-S05. Monoclonal Antibody development (Remote) OUTSTANDING
U02 (con U03)	3905	U2-S03. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S05. Monoclonal Antibody development (Remote) OUTSTANDING
U02	3897	U2-S03. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING
U02	3898	U2-S03. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U03 (con U02)	3905	U3-S01. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U06 (con U16)	3895	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote)
U06 (con U20)	3896	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote)
U06	3900	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S02. High-pressure phase analysis – solubility, emulsification OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S08. Tangential flow filtration

U06	3901	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S07. Interactions of two biomolecules with respect to binding kinetics and affinity by surface plasmon resonance (SPR), U6-S08. Tangential flow filtration ^{oo}
U06	3807	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U06	3833	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U06	3838	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U06	3839	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U06	3846	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U07	3802	U7-S01. Training Courses in the Use of nanotechnology equipment (Onsite), U7-S03. Characterization by SEM (On-site&Remote) OUTSTANDING, U7-S07. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING, U7-S08. Fabrication of Chromium masks (Remote) OUTSTANDING, U7-S09. Thin layer deposition (Remote) OUTSTANDING, U7-S10. Advising and consulting in micro and nanofabrication (On-site&Remote)
U07	3821	U7-S01. Training Courses in the Use of nanotechnology equipment (Onsite), U7-S07. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING, U7-S08. Fabrication of Chromium masks (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U09	3917	U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING, U9-S06. Consultancy on Synthesis and Characterization of Nanoparticles (Remote)
U09	3916	U9-S02. Synthesis of Nanoparticles by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING, U9-S06. Consultancy on Synthesis and Characterization of Nanoparticles (Remote)

U09	3919	U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING, U9-S04. Microfluidics and microwave-assisted production of nanoparticles (Remote) OUTSTANDING, U9-S06. Consultancy on Synthesis and Characterization of Nanoparticles (Remote)
U09	3920	U9-S02. Synthesis of Nanoparticles by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
U09	3921	U9-S01. Synthesis of Nanoparticles by laser induced-pyrolysis (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
U09	3918	U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U10	3841	U10-S08. 3D bio-impression of scaffolding for regenerative medicine (On-site&Remote) OUTSTANDING
U10	3844	U10-S01. Design & Development of pharmaceutical forms (Remote) OUTSTANDING, U10-S03. Design & Development of solid lipid nanoparticules(SLN) (Remote) OUTSTANDING, U10-S09. Characterization and development of pulmonary formulations (On-site&Remote) OUTSTANDING
U10	3842	U10-S09. Characterization and development of pulmonary formulations (On-site&Remote) OUTSTANDING
U10	3843	U10-S01. Design & Development of pharmaceutical forms (Remote) OUTSTANDING, U10-S03. Design & Development of solid lipid nanoparticules(SLN) (Remote) OUTSTANDING, U10-S09. Characterization and development of pulmonary formulations (On-site&Remote) OUTSTANDING
U10	3899	U10-S01. Design & Development of pharmaceutical forms (Remote) OUTSTANDING, U10-S03. Design & Development of solid lipid nanoparticules(SLN) (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U12	3852	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING, U12-S04. Rheology, viscometry and densimetry (Remote) OUTSTANDING, U12-S05. Surface and interfacial tensiometry (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING, U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING

U12	3853	U12-S04. Rheology, viscometry and densimetry (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING, U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING
U12	3848	U12-S06. Surface hydrophobicity characterization (Remote) OUTSTANDING, U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING
U12	3822	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING, U12-S04. Rheology, viscometry and densimetry (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING
U12	3808	U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING
U12	3880	U12. Nanostructured liquid characterization unit
U12	3883	U12-S02. Measuring nanoparticles aggregation properties and surface area (Remote) OUTSTANDING, U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U13	3924	U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING
U13	3925	U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S09. COMPRESSION-SHEAR TEST CELLSCALE MicroTester G2 (On-site) OUTSTANDING
U13 (con U14, U21 y U22)	3891	U13-S03. FATIGUE TESTS INSTRON 8874 (Remote) OUTSTANDING, U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING U22-S01. Animal Housing (Remote) OUTSTANDING
U13	3926	U13-S03. FATIGUE TESTS INSTRON 8874 (Remote) OUTSTANDING, U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
--------	-----------	--------------------

U14 (con U20, U21, U22)	3888	U14-S01. Cell cultures (Onsite&Remote)
U14 (con 21, 22, 24)	3849	U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING
U14	3889	U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING
U14 (con U13, U21 y U22)	3891	U13-S03. FATIGUE TESTS INSTRON 8874 (Remote) OUTSTANDING, U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING
U14 (con 19, 22)	3851	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING U22-S01. Animal Housing (Remote) OUTSTANDING
U14 (con 21, 22)	3903	U14-S04. Cytokine quantification assays (On-site&Remote) OUTSTANDING
U14 (con U19, U22, U23, U24)	3805	U14-S02. Flow Cytometry (Onsite&Remote) OUTSTANDING, U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING, U14-S02. Flow Cytometry (Onsite&Remote) OUTSTANDING, U14-S04. Cytokine quantification assays (On-site&Remote) OUTSTANDING, U14-S05. Determination of cytokine concentration by flow cytometry (On-site&Remote) OUTSTANDING, U14-S06. Lymphocyte proliferation assay (On-site&Remote) OUTSTANDING
U14	3806	U14-S02. Flow Cytometry (Onsite&Remote) OUTSTANDING
U14 (con U19, U22)	3823	U14-S04. Cytokine quantification assays (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U16 (con U06)	3895	U16-S07. Evaluation of the adhesion capacities and formation of bilayers of microorganisms on materials. OUSTANDING
U16	3825	U16-S05. DROP SHAPE ANALYZER – DSA100E – Goniomete- (Remote) OUTSTANDING, U16-S09. Kelvin Probe Force Microscopy (KPFM)
U16	3827	U16-S05. DROP SHAPE ANALYZER – DSA100E – Goniomete- (Remote) OUTSTANDING, U16-S09. Kelvin Probe Force Microscopy (KPFM)
U16	3824	U16-S07. Evaluation of the adhesion capacities and formation of bilayers of microorganisms on materials. OUSTANDING, U16-S09. Kelvin Probe Force Microscopy (KPFM)
U16	3828	U16-S04. Characterization by Tof-SIM (Remote) OUTSTANDING
U16	3829	U16-S04. Characterization by Tof-SIM (Remote) OUTSTANDING
U16	3830	U16-S01. XPS (Remote) OUTSTANDING
U16	3831	U16-S01. XPS (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U17	3801	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3873	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING

U17	3893	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3904	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3826	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3832	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3837	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3858	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U18	3861	U18-S01. In vitro Toxicology (Remote) OUTSTANDING, U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3884	U18-S01. In vitro Toxicology (Remote) OUTSTANDING, U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3911	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3912	U18-S01. In vitro Toxicology (Remote) OUTSTANDING, U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3914	U18-S01. In vitro Toxicology (Remote) OUTSTANDING
U18	3915	U18-S01. In vitro Toxicology (Remote) OUTSTANDING
U18	3809	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3811	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3813	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3815	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3816	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3817	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3819	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3820	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U19 (con 21, 24)	3877	U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING
U19 (con 21)	3879	U19-S01. Preclinical Studies (Onsite&Remote) OUTSTANDING, U19-S02. Animal Model Studies (Onsite&Remote) OUTSTANDING, U19-S03
U19 (con 21)	3876	U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING

U19 (con 21, 22, 24)	3908	U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING
U19 (con 21, 24)	3875	U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING
U19 (con 21)	3878	U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING
U19 (con 21, 22, 24)	3862	U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING
U19 (con U14 y U22)	3823	U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING
U19 (con U14, U22, U23 U24)	3805	U19-S01. Preclinical Studies (Onsite&Remote) OUTSTANDING, U19-S02. Animal Model Studies (Onsite&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U20 (con U06)	3896	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING, U20-S02. Preclinical Experimental consultancy (Remote) OUTSTANDING, U20-S05. In vitro Efficacy assays of drugs, nanomedicines, biomaterials and others, U20-S08. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING, U20-S11. In vivo PK/PD assays (Remote) OUTSTANDING
U20	3854	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING
U20	3855	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING
U20	3856	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING
U20	3835	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING
U20	3857	U20-S08. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
U20	3909	U20-S07. Animal models in oncology (Orthotopic, subcutaneous, intrasplenic and intravenous cell inoculation in syngeneic and immunodeficient mice (Remote) OUTSTANDING, U20-S08. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
U20	3913	U20-S05. In vitro Efficacy assays of drugs, nanomedicines, biomaterials and others, U20-S08. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
U20	3923	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING
U20	3803	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING

U20	3859	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING, U20-S08. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING, U20-S10. In vivo ADME and biodistribution assays (Remote) OUTSTANDING
U20	3886	U20+A117:D128S02. Preclinical Experimental consultancy (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U21 (con U14, U20, U22)	3888	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
U21 (con U22)	3874	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
U21 (con U22)	3887	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
U21 (con U22, U24)	3892	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
U21 (con U13, U14 y U22)	3891	U13-S03. FATIGUE TESTS INSTRON 8874 (Remote) OUTSTANDING, U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING U22-S01. Animal Housing (Remote) OUTSTANDING
U21 (con U22, U24)	3845	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U22 (con U14, U20, U21)	3888	U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote)
U22 (con U21)	3874	U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote)
U22 (con U21)	3887	U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING
U22 (con U13, U14 y U21)	3891	U13-S03. FATIGUE TESTS INSTRON 8874 (Remote) OUTSTANDING, U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING U22-S01. Animal Housing (Remote) OUTSTANDING
U22 (con U21, U24)	3892	U22-S01. Animal Housing (Remote) OUTSTANDING
U22 (con U21, U24)	3845	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S07. Development of animal models of disease in large animals (On-site)

U22 (con U14, U19, U23 U24)	3805	U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote), U22-S07. Development of animal models of disease in large animals (On-site)
U22 (con U14, U19)	3823	U22-S01. Animal Housing (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U23	3907	U23-S01. In vitro fertilisation studies and embryo culture media viability (Onsite&Remote) OUTSTANDING, U23-S02. Embryo culture media viability studies (On-site&Remote) OUTSTANDING, U23-S04. Sperm, Oocyte and embryo cryopreservation (Onsite&Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site&Remote) OUTSTANDING
U23	3910	U23-S01. In vitro fertilisation studies and embryo culture media viability (Onsite&Remote) OUTSTANDING, U23-S02. Embryo culture media viability studies (On-site&Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site&Remote) OUTSTANDING
U23	3882	U23-S09. Quality control for Human Assisted Reproduction clinics (On-site&Remote) OUTSTANDING
U22 (con U14, U19, U23 U24)	3805	U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote), U22-S07. Development of animal models of disease in large animals (On-site)

Unidad	Solicitud	Descripción Acceso
U24 (con U21, U22)	3892	U24-S02. Medical Imaging for Minimum Invasive Surgery
U24 (con U21, U22)	3845	U24-S02. Medical Imaging for Minimum Invasive Surgery
U24 (con U14, U19, U22, U23)	3805	U24-S02. Medical Imaging for Minimum Invasive Surgery

Unidad	Solicitud	Descripción Acceso
U25	3922	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING
U25	3881	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U26	3906	U26-S06. Biomedical and metabolomic imaging (On-site)
U26	3840	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
U26	3847	U26-S06. Biomedical and metabolomic imaging (On-site)
U26	3850	U26-S06. Biomedical and metabolomic imaging (On-site)
U26	3860	U26-S06. Biomedical and metabolomic imaging (On-site)
U26	3890	U26-S06. Biomedical and metabolomic imaging (On-site)

Unidad	Solicitud	Descripción Acceso
U28	3804	U28-S016. Confocal Microscopy (Onsite&Remote) OUTSTANDING
U28	3834	U28-S01. Magnetic Resonance Imaging (MRI) (Onsite&Remote) OUTSTANDING, U28-S04. High Resolution Liquid NMR (Onsite&Remote) OUTSTANDING, U28-S05. High Resolution Magic Angle Spinning (HR-MAS) NMR (Onsite&Remote), U28-S012. Cryo-ultramicrotomy (Onsite&Remote) OUTSTANDING, U28-S016. Confocal Microscopy (Onsite&Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (Onsite&Remote)
Unidad	Solicitud	Descripción Acceso
U29	3885	U29-S01. Synthesis of oligonucleotides and characterization (On-site & Remote). OUTSTANDING, U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING

5 de julio de 2024

Comité de Coordinación de NANBIOSIS